Scholars@Duke
Nirmish Ramesh Shah

Nirmish Ramesh Shah

Associate Professor of Medicine
Medicine, Hematology
nirmish.shah@duke.edu
Department of Medicine, Duke S, Durham, NC 27710
Department of Medicine, Duke S, Durham, NC 27710

Scholarly Works - Conferences

Feasibility of wearable technology for remote monitoring in high-risk adults with sickle cell disease: Baseline data from the SCD-carre trial

Conference Blood · November 3, 2025 AbstractBackground: Adults with sickle cell disease (SCD) experience reduced physical capacity due to anemia and cardiopulmonary complicati ... Full text Cite

Exploring Differences in Hospital Readmissions in Patients with Sickle Cell Disease By Examining Patterns with mHealth-Acquired Pain and Physiologic Data

Conference Blood · November 5, 2024 IntroductionVaso-occlusive crises (VOCs) are the most common reason for hospital admission for patients with sickle cell disease (SCD). Due to high rea ... Full text Cite

Setting Industry Standards for Patient Engagement, Partnership, Allyship and Care: The Patient Vision Project

Conference Blood · November 2, 2023 Background: Patient perspectives have shifted towards greater expectations of autonomy and personalized care, leading to growing demands for partnerships between patients, healthcare providers (HCPs), and industry. Such ... Full text Cite

Associations between Epigenetic Age Acceleration and Psychoneurological Symptoms in Sickle Cell Disease

Conference Blood · November 2, 2023 Introduction:Sickle cell disease (SCD) affects approximately 100,000 predominantly Black or African American individuals in the United States. The disease has several acute and chronic c ... Full text Cite

Sickle Cell Disease Management Practices across Nigeria: A Cross-Sectional Analysis

Conference Blood · November 2, 2023 IntroductionOf 300,000 children born with sickle cell disease (SCD) in the world, approximately 75% of these are born in Sub-Saharan Africa. Owing to the frequent painful vaso-occlusive ... Full text Cite

Cross-Community Collaboration and Data Collection to Optimize Patient Care in Hemolytic Anemias

Conference Blood · November 2, 2023 Background: Patient engagement is becoming increasingly important for all facets of healthcare, from drug development and approval, to ensuring equitable access and the delivery of care. It is imperative to bring the vo ... Full text Cite

Real-World Experience of Individuals with Sickle Cell Disease Treated with Voxelotor: Initial Report from the Multicenter, Prospective Prospect Study

Conference Blood · November 2, 2023 Introduction: Sickle cell disease (SCD) is an inherited blood disorder in which sickle hemoglobin (HbS) polymerization results in red blood cell sickling, which in turn leads to chronic hemolytic anemia, unpredictable p ... Full text Cite

Prevalence of High BMI Status in Adults with Sickle Cell Disease

Conference Blood · November 5, 2021 AbstractIntroductionEmerging literature suggests body mass index (BMI) may be increasing in individuals with sickle cell disease (SCD), a condition historically associated wi ... Full text Cite

Impact of Gaps in Care during Adult Care Transfer in Sickle Cell Disease

Conference Blood · November 5, 2021 AbstractThe transition from pediatric to adult health care is critical to the care of young adults with sickle cell disease (SCD). Young adults with SCD, compared with children with SCD, are at risk for a ma ... Full text Cite

Pain intensity assessment in sickle cell disease patients using vital signs during hospital visits

Conference Lecture Notes in Computer Science · January 1, 2021 Pain in sickle cell disease (SCD) is often associated with increased morbidity, mortality, and high healthcare costs. The standard method for predicting the absence, presence, and intensity of pain has long been self-report. However, medical providers stru ... Full text Cite

Real World Evidence of Prescription Patterns and Effect of Oxbryta (voxelotor) for Patients with Sickle Cell Disease

Conference Blood · November 5, 2020 Background: Sickle cell disease (SCD) is a chronic illness characterized by anemia, recurrent severe pain and recurrent organ damage, affecting approximately 100,000 persons in the United States. Prior to November 2019, FDA approved SCD disease-mod ... Full text Cite

Sex Based Differences in Sickle Cell Disease

Conference Blood · November 5, 2020 IntroductionSickle cell disease (SCD) is the most common inherited blood disorders in the United States. The disease predominantly affects African Americans with 1 out of every 365 individuals born with SCD. The dis ... Full text Cite

Predictors of Maternal Morbidity Among Participants Enrolled in the Sickle Cell Disease Implementation Consortium Registry

Conference Blood · November 5, 2020 IntroductionPregnancy in sickle cell disease (SCD) is associated with an exacerbation of SCD-related complications and an increased risk of maternal complications. The increased risk is partly due to physiologic ada ... Full text Cite

Measuring Pain in Sickle Cell Disease using Clinical Text

Conference Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society EMBS · July 1, 2020 Sickle Cell Disease (SCD) is a hereditary disorder of red blood cells in humans. Complications such as pain, stroke, and organ failure occur in SCD as malformed, sickled red blood cells passing through small blood vessels get trapped. Particularly, acute p ... Full text Cite

Hydroxyurea Prescription Fills and Adherence, Among Pediatric and Adult Medicaid Eligible Patients with Sickle Cell Disease in North Carolina

Conference Blood · November 13, 2019 Introduction: Sickle cell disease (SCD) is a complex disease for which pain is the hallmark. Hydroxyurea (HU) is the standard of care for treatment for most patients with SCD and reduces the frequency of pain episodes, acute chest syndrome, need fo ... Full text Cite

Emergency Department Encounters, Hospitalizations and ED Reliance Among Medicaid Eligible Patients with Sickle Cell Disease in North Carolina

Conference Blood · November 13, 2019 Introduction: Sickle cell disease (SCD) is a complex disease for which pain is the hallmark. Pain from vaso-occlusive episodes is the number one reason for ED visits and hospital admissions. This paper reports Medicaid claims data from NC for indiv ... Full text Cite

Continuous Pain Assessment Using Ensemble Feature Selection from Wearable Sensor Data.

Conference Proceedings (IEEE Int Conf Bioinformatics Biomed) · November 2019 Sickle cell disease (SCD) is a red blood cell disorder complicated by lifelong issues with pain. Management of SCD related pain is particularly challenging due to its subjective nature. Hence, the development of an objective automatic pain assessment metho ... Full text Link to item Cite

Outpatient Healthcare Utilization and Rates of Co-Management Among Medicaid Patients with Sickle Cell Disease in North Carolina

Conference Blood · November 29, 2018 AbstractIntroduction: Sickle cell disease (SCD) is a complex disease for which pain is the hallmark, often results in end-organ failure, and is associated with early death. Primary care providers (PCP's), he ... Full text Cite

Trajectories of Sickle Cell Disease Severity during Transition to Adult Care

Conference Blood · November 29, 2018 AbstractBackgroundAdolescents and young adults (AYAs) with sickle cell disease (SCD) are at increased risk for disease complications and mortality, particularly during transi ... Full text Cite

Hybrid Statistical and Mechanistic Mathematical Model Guides Mobile Health Intervention for Chronic Pain.

Conference J Comput Biol · July 2017 Nearly a quarter of visits to the emergency department are for conditions that could have been managed via outpatient treatment; improvements that allow patients to quickly recognize and receive appropriate treatment are crucial. The growing popularity of ... Full text Link to item Cite

Use of Mobile Technology to Monitor Pain and Reduce Outpatient, Emergency Department (ED), and Hospital Visits for Sickle Cell Pain Crisis

Conference Blood · December 2, 2016 AbstractIntroduction: Sickle cell disease (SCD) is a chronic illness associated with frequent medical complications and hospitalizations. Importantly, approximately ninety percent of hospitalizations are for ... Full text Cite

Timing of the Initiation of Hydroxyurea and Hematologic Outcomes in Patients with Sickle Cell Disease (SCD)

Conference Blood · November 16, 2012 AbstractAbstract 1004Hydroxyurea (HU) is approved for use in adults with Sickle Cell Disease (SCD) and increases the production of fetal hemoglobin (HbF). Increased HbF is as ... Full text Cite

Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up

Conference Blood · November 19, 2010 AbstractAbstract 206Background:Dasatinib is 325-fold more potent than imatinib in vitro against unmut ... Full text Cite